Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in HIV-positive adults with virologic response but poor immunologic response
IRCT20231124060158N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosuvastatin in human immunodeficiency virus infection (HIV), sponsored by Iran University of Medical Sciences. Primary endpoint: Change in CD4 count after rosuvastatin treatment. Started Aug 2019; status: completed.
02
Drugs
rosuvastatin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on IRCT20231124060158N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231124060158N1.